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Highlights: 
 Predictors of locoregional recurrence (LRR) may help to tailor radiotherapy 
 Second study using data from a prospective trial  
 Low 5-year LRR rate (4.90%), with only 76 patients with a LRR as first event  
 The highest LRR risk is observed in triple negative and HER2+ subtypes. 
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Abstract  
Purpose: Identification of clinico-pathological factors predicting for a locoregional recurrence 
(LRR) after neoadjuvant chemotherapy (NAC) could help to decide on the optimal 
locoregional radiotherapy. The objective of this trial is to identify those factors in the context 
of a phase III trial (EORTC 10994). 
Methods: Patients received NAC followed by surgery with or without radiotherapy. 
Radiotherapy was administered according to pre-specified guidelines. Patients with hormone 
receptor positive tumours received adjuvant hormonal therapy. A proportion of patients with 
Human Epidermal growth factor Receptor 2 (HER2) positive cancer received adjuvant 
trastuzumab. The predictive factors for LRR were identified by multivariate analysis with time 
to LRR as first event as the primary endpoint. 
Results: The median follow-up was 4.8 years. In 1553 eligible patients, there were 76 LRRs 
with a 5-year cumulative incidence of 4.9% (95% CI: [3.76-6.04]). In multivariate analysis, 
breast cancer subtype was a significant predictor of LRR (p<0.0001): Hazard Ratio (HR) 6.44 
(95% CI: [2.83-14.69]) for triple negative, 6.26 (95% CI: [2.81-13.93]) for HER2+ without 
trastuzumab (T), and 3.37 (95% CI [1.10-10.34]) for HER2+ with T cancers, all compared to 
Luminal A patients. Lack of pathological response was also associated with significantly higher 
LRR risk in case of ≥ 4 pathologically positive nodes, HR 2.43 (95% CI [1.34-4.40], p<0.0001).  
Conclusion: Breast cancer subtype and lack of pathological response are predictive factors 
for high LRR after NAC.  
Key words: Breast cancer, neoadjuvant chemotherapy, locoregional recurrence 
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Introduction 
Adjuvant radiotherapy indications after neoadjuvant chemotherapy (NAC) are, for now, based 
on the standard radiation indications (1). However, none of the studies that led to these 
indications included patients receiving NAC (2, 3).  
With regard to identified predictive factors of locoregional recurrence (LRR), the National 
Surgical Adjuvant Breast and Bowel Project (NSABP) study is the only published data from 
prospective trials (NSABP B-18, NSABP B-27) (4, 5). Several predictive factors of 10-year LRR 
risk were identified in that study: age <50 years (after lumpectomy), clinical tumour size >5 cm 
(after mastectomy), clinical nodal status (cN+), pathological breast tumour response (ypT+) 
and pathological nodal status (ypN+) (6).  
We therefore analysed data from the previously published EORTC 10994/BIG 1-00 
neoadjuvant phase III trial (7). The EORTC study is more recent compared to the NSABP study 
with significant therapeutic implications for radiotherapy indications, adjuvant hormonal 
therapy and trastuzumab. We included two pathological factors in our analysis: the 
pathological response after chemotherapy and a simplified breast cancer subtype 
classification. The latter consists of 4 groups: luminal A-like, luminal B-like, Human Epidermal 
growth factor Receptor 2 (HER2) positive and triple negative (supplementary table 1). In the 
EORTC 10994 study, only a third of the patients with HER2-positive tumours received adjuvant 
trastuzumab. This treatment became the new standard of care for HER2-positive patients at 
the end of the EORTC 10994/BIG 1-00 trial (8, 9). Since trastuzumab treatment is known to 
reduce the risk of relapse including LRR (10), the HER2-positive group was further divided in 
two subgroups: patients who did or did not receive adjuvant trastuzumab. Our aim is to 
examine rates and patterns of LRR and to identify predictive factors in breast cancer patients 
treated with NAC. 
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Methods 
Study design, eligibility and treatments 
This was an unplanned analysis of the EORTC 10994/BIG 1-00 neoadjuvant phase III trial 
randomizing patients in a 1:1 ratio between six cycles of fluorouracil, epirubicin, 
cyclophosphamide and a taxane-based regimen, docetaxel for three cycles followed by 
epirubicin+ docetaxel for three cycles, all administered prior to primary surgery (7). The trial 
was registered with ClinicalTrials.gov number NCT00017095 and was approved by national 
and/or local ethics committees in all participating centres. All patients signed an informed 
consent for the clinical trial and for research on tumour samples taken before registration and 
randomization. Eligible patients for the EORTC 10994 trial were women aged <71 years 
suitable for NAC, with histologically-proven invasive carcinoma of the breast, with any large 
operable or locally advanced/inflammatory breast cancer. Following surgery, treatment was 
completed with planned radiotherapy in accordance with the guidelines described in the 
protocol (supplementary file). Adjuvant endocrine therapy for 5 years was mandatory for 
women with Oestrogen Receptor (ER) and/or Progesterone Receptor (PR) positive tumours. 
Patients with HER2-positive tumours were allowed to take part in adjuvant clinical trials 
assessing trastuzumab or to receive this treatment in the adjuvant setting when it became 
standard practice, but not to receive it neo-adjuvantly.  
For this sub-study, a subgroup of the initial population of 1856 patients was selected based on 
the following criteria: (i) eligible patients from the EORTC 10994 trial (ii) patients who received 
at least one cycle of NAC and who underwent surgery of the primary tumour and axilla; (iii) 
patients who didn’t receive radiotherapy before surgery; (iv) patients who did not progress on 
NAC; (v) patients without inflammatory breast cancer.  
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Objectives and endpoints definitions 
The primary objective was to identify predictive factors for LRR as first relapse after NAC and 
locoregional treatment. The secondary objective was to describe the LRR rate and patterns 
and the time to LRR as first relapse. 
The time to LRR was defined as the time in days from the date of surgery to the date of a 
locoregional recurrence as a first relapse. LRRs were reported by the investigators on a case 
report form. Regional recurrences sites were classified as skin and/or chest wall, axillary lymph 
nodes, internal mammary nodes and infra/supraclavicular nodes relapses. Patients who died 
or experienced a distant relapse or a second primary cancer prior to or within a window of 2 
months following a LRR (STEEP system) were considered as having had a competing risk 
event at the time of the competing event (11). Patients without an event of interest or a 
competing risk event were censored at their last follow-up date. 
 
Pathology assessment 
No central pathology review was performed for this analysis. Grade, ER, PR, and HER2 status 
were assessed by local pathologists from biopsy taken at diagnosis and reported on a case 
report form. ER, PR and HER2 status was assessed by immunohistochemistry (IHC) and 
reported as positive or negative according to each center’s local definition. HER2-positivity 
was defined as either HER2 gene amplification by fluorescent in situ hybridization and/or 
scored 3+ by IHC. As the information on Ki-67 was not available from data collected within the 
main EORTC 10994 study, we replaced Ki-67 by grade in order to classify tumours in luminal 
A-like or luminal B-like groups, based on the St Gallen 2011 consensus (supplementary table 
1) (12). Pathological response was assessed by local pathologists by microscopic examination 
of the excised tumour and lymph nodes after completion of the NAC. Pathological complete 
response (pCR) was defined as no evidence of residual invasive cancer (or very few scattered 
tumour cells) in the primary tumour, with or without residual ductal carcinoma in situ, and in 
axillary lymph nodes (ypT0/is ypN0) (US FDA suggested definition) (13). Surgical margins 
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were defined as negative (R0) when no invasive or in situ carcinoma cell was seen on the 
inked section, or as positive (R1) otherwise. 
 
Statistical analysis 
A statistical analysis plan was prospectively defined. Eligible patients were analysed on an 
intent-to-treat basis. All the statistical analyses were performed using SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA). The following variables were tested as potential predictive 
factors for LRR as first event: age at diagnosis, cT, cN, type of surgery 
(lumpectomy/quadrantectomy, mastectomy), histological type (ductal, lobular, other), surgical 
margins (R0, R1), pathological tumour/nodal status after NAC (ypT0/is ypN0, ypT+ (any size) 
ypN0, ypT+ (any size) ypN+ 1-3 nodes, ypT+ (any size) ypN+ ≥4 nodes), and simplified breast 
cancer subtypes classification with 6 groups, luminal A-like, luminal B-like (HER2-), HER2+ 
Trastu- (not treated with trastuzumab), HER2+ Trastu+ (treated with trastuzumab), triple 
negative, unknown.  
A backward model selection procedure was performed starting from a full multivariate Fine and 
Gray model containing all potential predictive factors (14). The selection procedure was 
stopped when all remaining factors in the model were significant at the 5% level according to 
the 2-sided Fine and Gray test p-value. The prognostic effect of these factors was quantified 
by the corresponding hazard ratio (HR) estimates with their 95% confidence interval (CI) in the 
final multivariate Fine and Gray model. These remaining factors were considered predictors 
for LRR as first relapse after NAC in this analysis. Patients with missing value(s) for one (or 
more) of the considered variables were excluded from the primary analysis. A sensitivity 
analysis was done, using a Cox model in which the competing events were censored, in order 
to validate the obtained results. An internal validation was also conducted via bootstrap 
resampling, to confirm the stability of the remaining factors. LRR cumulative incidence curves 
were generated using Kaplan Meier method. 
 
 8 
Results 
Characteristics of the patient population 
Of the 1856 patients originally randomised, 1553 patients were eligible for this sub-study. The 
reasons for ineligibility are provided in the consort diagram (figure 1). The clinicopathological 
characteristics of the patients are shown in table 1.  
 
Rates and cumulative incidence of LRRs 
Median follow-up was 4.4 years (95% CI, [4.2-4.5]) from the date of surgery. A total of 76 
patients presented with a LRR as first relapse. Table 1 shows the number of patients (and 
rates) with LRR as first relapse according to patient and tumour characteristics. Competing 
events were observed in 351 patients (distant relapse in 350 and death in 1). Cumulative 
incidence curves of LRR as first event and of competing events are reported in figure 2. The 
LRR rate at 5 years was 4.9% (95% CI,[3.76-6.04]) and the local relapse only as first relapse 
rate at 5 years was 1.9% (95% CI,[1.2-2.8]). 
 
Patterns of LRRs as first event 
Of the 76 patients with observed LRR as first relapse, 27 (35.5%) had local recurrences only, 
4 had local and regional recurrences (5.3%) and 45 (59.2%) had regional recurrences only 
(one regional site or more).  
Details of LRRs are provided in table 2. Sites of relapse were local in 31 patients, chest wall 
relapses in 28, axillary nodes in 11, internal mammary nodes in 3, infraclavicular nodes in 6 
and subclavicular nodes in 8. Recurrences were preferentially isolated among patients with 
local recurrences (27/31 cases (87.1%)) and with infra/supraclavicular node recurrences 
(10/14 cases (71.4%)). They were frequently accompanied by another site of relapse among 
patients with regional axillary nodes recurrences (7/11 cases (63.6%)) and internal mammary 
node recurrences (2/3 cases (66.7%). LRRs predominantly occurred in the first 3 years of 
follow-up (figure 2). However, some LRRs were observed over 7 years after date of surgery.  
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Predictive factors for LRRs 
Due to missing data, 48 of the 1553 eligible patients were excluded (figure 1) for the principal 
multivariate analysis (table 3). Two factors were identified as being independent predictors of 
LRR as first event after NAC: breast cancer subtype classification and pathological response 
(p <0.0001 for both factors).  
The luminal A-like group, used as the reference, had lower risk of LRR. In the final multivariate 
Fine and Gray model, luminal B-like, HER2+ Trastu-, HER2+ Trastu+ and triple negative 
groups had a higher risk of LRR: HR 2.29 (95% CI,[0.76-6.97]), 6.26 (95% CI,[2.81–13.93]), 
3.37 (95% CI,[1.10–10.34]), and 6.44 (95% CI,[2.83–14.69]), respectively. Although no direct 
comparison was made between these groups, the risk of LRR tended to be lower among 
patients with HER2-positive cancer when treated with adjuvant trastuzumab. 
Concerning the pathological response, the ypT0/is ypN0 group was taken as the reference 
group. The main difference between the groups is driven by the increased risk of LRR for the 
ypT+ (any size) ypN+ >4 nodes group (HR 2.43; 95% CI,[1.34–4.40]). By contrast, a lower risk 
of LRR was observed in the ypT+ (any size) ypN0 and ypT+ (any size) ypN+ 1-3 nodes groups 
(HR 0.58 [0.26–1.28] and HR 0.74 [0.36–1.52]) although the CIs were large. Of note, 16 
patients with a pCR presented a LRR as first site of relapse of whom 10 presented a local 
relapse only (supplementary table 2). 
The other tested factors (age, cT, cN, histological type, type of surgery and surgical margins) 
were not significantly associated with the occurrence of LRR as first relapse in this analysis. 
Sensitivity analyses using a backward procedure on Cox models in which the competing 
events are censored, selected the same factors for prediction of LRR as first event. Internal 
validation via bootstrap resampling of this model confirms the stability of these two factors 
(supplementary table 3). 
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Discussion 
The first notable observation of this study is the low 5-year LRR rate (4.90%), with only 76 / 
1553 patients presenting with a LRR as first event. In the retrospective studies published from 
2002 to 2005, the 5-year LRR rate was higher (ranging from 10-27%) (15-18) decreasing in 
more recent publications (ranging from 4.6-11%) (19-23). In the NSABP study, the 10-year 
LRR rate was 11.1% (6). Given that pre-operative breast MRI was exceptionally performed at 
that time and radiopaque markers were rarely inserted in the tumours, it may be that the lower 
LRR observed in EORTC trial could be due to improvements in radiotherapy, hormonal therapy 
and trastuzumab use. Adjuvant radiotherapy was more widely used in EORTC trial, with strict 
guidelines provided in the study protocol (see Appendix). The indications of adjuvant hormone 
therapy have evolved in recent years. In NSABP B-18 trial, only patients >50yrs received 
tamoxifen. In EORTC trial, tamoxifen (or aromatase inhibitors for postmenopausal patients) 
was given to all patients with positive ER and/or PR cancers; one third of patients with HER2-
positive cancer received adjuvant trastuzumab.  
 
The second key finding of our study is the demonstration of a statistically predictive role of 
breast cancer subtypes on LRR risk after NAC, particularly for triple negative and HER2-
Positive subtypes (irrespective of adjuvant trastuzumab treatment). In EORTC trial, the highest 
LRR risk was observed in triple negative and HER2+ Trastu- groups with high HRs (6.44 and 
6.26, respectively). Although breast cancer subtypes were not analysed in NSABP study (6), 
the role of subtypes on LRR risk had been suggested in smaller retrospective studies 
(20,21,23). Our analysis corroborated these initial results with greater robustness. Regarding 
the role of adjuvant trastuzumab, estimated LRR risk was nearly two times higher for HER2 
Trastu- than for HER+ Trastu+ cancers. Although no direct comparison could be made 
between these 2 groups, adjuvant trastuzumab certainly plays a role. Its protective effect on 
LRR after NAC had been suggested in two recently published retrospective studies from the 
MDACC and the Korean groups (22,23). Luminal A-like and luminal B-like (HER2-negative) 
 11 
cancers showed lower LRR rates. However, breast luminal A and B cancers continue to 
relapse beyond 5 years after the initial diagnosis, whereas later relapses of other subtypes are 
rare. We acknowledge that the follow-up might be to short. Hence, another analysis of the 
EORTC study based on long-term follow-up data is planned in late 2017. 
 
In our study, pathological response was the only other predictive factor for LRR. The main 
difference between the groups was not driven by a decreased risk in patients achieving a pCR 
group, but by an increased risk of LRR for the ypTx (any size) ypN+ ≥4 nodes subgroup. Our 
finding is consistent with literature, pathological nodal involvement having already been 
identified as a predictor of LRR, with a greater risk when 4 nodes or more were involved 
(6,15,16,21).  The ongoing NSABP B-51/RTOG 1304 phase III trial will enlighten the real 
benefit of postmastectomy regional node radiotherapy for cN+ypN0 patients (NCT01872975). 
  
Our study has several limitations. First, though precise guidelines for adjuvant radiotherapy 
were provided (supplementary file), data as to precisely what radiotherapy was given to each 
patient was not captured in the CRFs. Second, the number of local and/or regional recurrence 
events in this study was low, therefore the analysis was only powered to pick up large effects 
for such small groups. This may explain why several factors previously identified  in the 
literature, such as surgical margins, age, clinical tumour status (cT) and clinical nodal status 
(cN), despite being tested, were not retained in this multivariate analysis (6, 15-17, 19, 22, 23).  
 
Conclusion 
Despite the low number of events observed in our analysis, we identified triple negative and 
HER2-positive breast cancer subtypes, regardless of adjuvant trastuzumab treatment, as 
being at high risk of developing loco-regional recurrence during the first 5 years after surgery. 
Thus, breast cancer subtype should be taken in consideration when considering regional nodal 
radiotherapy following surgery. Pathological involvement of at least 4 nodes was also found to 
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be predictive of a higher LRR risk. Importantly, even when a pCR was obtained after NAC, 
some patients experienced a LRR and based on this observation, a de-escalation of adjuvant 
radiotherapy indication should not be considered outside of a prospective trial in patients 
achieving a pCR. 
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Figure Legends 
Figure 1: Consort diagram. *Patients can be excluded for more than one criteria;  
**Ineligibility reasons in EORTC 10994 trial are displayed in the final analysis publication (7). 
 
Figure 2: Cumulative incidence of locoregional relapse as first event and related competing 
risks. Locoregional relapse as first relapse is indicated in red, competing events such as 
distant relapse or second cancer prior to or concurrent with locoregional relapse or death are 
in blue and all aforementioned events in cyan.  
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Figure 1 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviation: LRR: locoregional recurrence.
303 ineligible patients*: 
 22 ineligible in EORTC 10994/BIG 1-00 trial** 
   6 did not receive at least one cycle of neoadjuvant chemotherapy 
153 T4d tumour 
  31 received radiotherapy before surgery 
110 showed progression disease before surgery 
 26 had no surgery 
1553 eligible patients 
48 patients with missing data on tested variables 
1505 patients 
Multivariate analysis 
128 patients with LRR 
14 concurrent distant relapses (within 2 month-window) 
38 prior distant relapses  
76 patients with a LRR event of interest 
(LRR as first event) 
74 patients with a LRR event of interest 
1856 randomised patients from EORTC 10994/BIG 1-00 trial 
 17 
Figure 2  
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Table 1: Patients and tumours characteristics 
 
Characteristics Patients  
with LRR as first event 
 
 No 
 (N = 1477)  
N (%)* 
Yes 
 (N = 76)  
N (%)* 
Total  
(N = 1553) 
N (%)* 
Age at diagnosis (years) 
≤ 40 
41 - 50 
51 – 70 
 
292 (93.3) 
579 (95.2) 
606 (95.9) 
 
21 (6.7) 
29 (4.8) 
26 (4.1) 
 
313 (20.2) 
608 (39.2) 
632 (40.7) 
Clinical tumour status (cT) 
cT1 – 2 
cT3 
cT4 
cTx 
 
837 (96.5) 
487 (94.0) 
152 (91.0) 
1 (100.0) 
 
30 (3.5) 
31 (6.0) 
15 (9.0) 
0 (0.0) 
 
867 (55.8) 
518 (33.4) 
167 (10.8) 
1 (0.1) 
Clinical nodal status (cN) 
cN0 
cN+ 
cNx 
 
675 (96.7) 
800 (93.8) 
2 (100.0) 
 
23 (3.3) 
53 (6.2) 
0 (0.0) 
 
698 (44.9) 
853 (54.9) 
2 (0.1) 
Type of surgery 
Lumpectomy or quadrantectomy 
Mastectomy 
 
690 (95.4) 
787 (94.8) 
 
33 (4.6) 
43 (5.2) 
 
723 (46.6) 
830 (53.4) 
Histological type 
Ductal 
Lobular 
Other 
Unknown 
 
1218 (94.7) 
172 (96.6) 
75 (97.4) 
12 (100.0) 
 
68 (5.3) 
6 (3.4) 
2 (2.6) 
0 (0.0) 
 
1286 (82.8) 
178 (11.5) 
77 (5.0) 
12 (0.8) 
Histological grade 
1 
2 
3 
Not known or not assessable 
 
109 (97.3) 
703 (95.8) 
457 (93.3) 
208 (95.9) 
 
3 (2.7) 
31 (4.2) 
33 (6.7) 
9 (4.1) 
 
112 (7.2) 
734 (47.3) 
490 (31.6) 
217 (14.0) 
Breast cancer subtype/trastuzumab 
Luminal A-like 
Luminal B-like (HER2-) 
HER2+ Trastu- 
 
489 (98.4) 
142 (96.6) 
225 (89.6) 
 
8 (1.6) 
5 (3.4) 
26 (10.4) 
 
497 (32.0) 
147 (9.5) 
251 (16.2) 
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HER2+ Trastu+ 
Triple negative 
Unknown 
105 (94.6) 
204 (91.1) 
312 (96.6) 
6 (5.4) 
20 (8.9) 
11 (3.4) 
111 (7.1) 
224 (14.4) 
323 (20.8) 
Pathological response 
ypT0/is ypN0 
ypT+ ypN0 
ypTx ypN+ 1-3 nodes 
ypTx ypN+ ≥4 nodes 
Unknown 
 
267 (94.3) 
416 (97.7) 
446 (97.0) 
332 (90.5) 
16 (94.1) 
 
16 (5.7) 
10 (2.3) 
14 (3.0) 
35 (9.5) 
1 (5.9) 
 
283 (18.2) 
426 (27.4) 
460 (29.6) 
367 (23.6) 
17 (1.1) 
Surgical margins 
R0  
R1 
Unknown 
 
1360 (95.4) 
100 (91.7) 
17 (94.4) 
 
66 (4.6) 
9 (8.3) 
1 (5.6) 
 
1426 (91.8) 
109 (7.0) 
18 (1.2) 
Adjuvant hormonotherapy 
ER+ and/or PR+ without hormonotherapy 
ER+ and/or PR+ with hormonotherapy 
ER- and PR-  
Unknown 
 
22 (84.6) 
1020 (97.1) 
339 (90.2) 
96 (95.0) 
 
4 (15.4) 
30 (2.9) 
37 (9.8) 
5 (5.0) 
 
26 (1.7) 
1050 (67.6) 
376 (24.2) 
101 (6.5) 
 
 
Abbreviations:  
ER: oestrogen receptor; PR: progesterone receptor; HER2: Human Epidermal growth factor 
Receptor 2; Trastu-: without adjuvant trastuzumab; Trastu+: with adjuvant trastuzumab; LRR: 
Locoregional recurrence; R0: negative surgical margins; R1: positive surgical margins. 
Legend: 
* Percentages are displayed as row percentages in the LRR as first events columns (no/yes) 
and as column percentages in the total column. 
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Table 2: Patterns of locoregional recurrences as first event, number of involved sites 
per patient and time to LRR from date of surgery by site of relapse. 
 
 
Site of LRR as 
first event 
Total number of 
involved sites 
Number of involved sites 
per patient  
 
Time to LRR from date of 
surgery (years) 
  
 
N (%) 
1 site 
(N = 65) 
N (%) 
≥ 2 sites 
(N = 11) 
N (%) 
 
Median in 
years 
(95% CI) 
 
Min – Max 
(years) 
Local    31 (40.8)                                                                                          27 (41.5)                                                                                          4 (36.4)                         1.72
(1.16- 2.35) 
0.44-7.13
Chest wall   28 (36.8)                                                                                          23 (35.4)                                                                                          5 (45.5)                         0.98
(0.53-1.10)              
0.12-6.90
Axillary nodes   11 (14.5)                                                                                             4 (6.2)                               7 (63.6)                             2.44
(0.26- 4.17) 
0.25-6.46
Internal 
mammary 
nodes 
   3 (3.9)                                                                                           1 (1.5)                                                                                           2 (18.2)                          1.15
(0.88- 2.27) 
0.88-2.27
Infraclavicular 
nodes  
   6 (7.9)                                                                                           4 (6.2)                                                                                           2 (18.2)                          2.00
(0.65- 4.30) 
0.64-4.31
Supraclavicular 
nodes 
   8 (10.5)                                                                                          6 (9.2)                                                                                           2 (18.2)                          1.72
(0.06- 4.12)              
0.06-4.31
 
 
Abbreviations:  
LRR: Locoregional recurrence; CI: confidence interval; Min: minimum; Max: maximum. 
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Table 3: Multivariate analysis for predictive factors of locoregional recurrence as first event at 5 years 
Potential predictive factors 
Full 
Multivariate Fine 
and Gray model  
Backward 
procedure 
selection 
Final 
Multivariate Fine and Gray model 
 
Patients 
(N (%)) 
(N = 1505) 
LRR as first 
event 
(N (%)) 
(N = 74) 
Competing 
events 
(N (%)) 
(N = 341) 
 
HR (95% CI) 
 
(Yes/No) 
 
HR (95% CI) 
2-sided 
p-Value 
(Gray test) 
Age at diagnosis (years) 
≤ 40 
41-50 
51-70 
 
303 (20.1) 
592 (39.3) 
610 (40 .5) 
 
21 (28.4) 
28 (37.8) 
25 (33.8) 
 
82 (24.0) 
116 (34.0) 
143 (41.9) 
 
1.00 
0.83 (0.45-1.54) 
0.61 (0.34-1.12) 
 
No 
  
Clinical tumour status (cT) 
cT1-2 
cT3 
cT4 
 
838 (55.7) 
507 (33.7) 
160 (10.6) 
 
30 (40.5) 
29 (39.2) 
15 (20.3) 
 
128 (37.5) 
153 (44.9) 
60 (17.6) 
 
1.00 
1.50 (0.80-2.78) 
2.16 (1.01-4.61) 
 
No 
  
Clinical nodal status (cN) 
cN0 
cN+ 
  
674 (44.8) 
831 (55.2)                                                                                        
 
23 (31.1) 
51 (68.9)
 
101 (29.6) 
240 (70.4)
 
1.00 
1.27 (0.75-2.13) 
 
No 
  
Type of surgery 
Lumpectomy 
or quadrantectomy 
Mastectomy 
 
702 (46.6)  
 
803 (53.4) 
 
33 (44.6) 
 
41 (55.4) 
 
106 (31.1) 
 
235 (68.9) 
 
1.00 
 
0.71 (0.39-1.28) 
 
No 
  
Histological type 
Ductal 
Lobular 
Other 
 
1256 (83.5) 
176 (11.7) 
73 (4.9) 
 
66 (89.2) 
6 (8.1) 
2 (2.7) 
 
282 (82.7) 
41 (12.0) 
18 (5.3) 
 
1.00 
0.79 (0.34-1.86) 
0.39 (0.10-1.63) 
 
No 
  
Breast cancer subtype / 
trastuzumab 
Luminal A 
Luminal B (HER2-) 
HER2+ Trastu- 
HER2+ Trastu+ 
Triple negative 
 
 
491 (32.6) 
143 (9.5) 
245 (16.3) 
105 (7.0) 
219 (14.6) 
 
 
8 (10.8) 
5 (6.8) 
25 (33.8) 
5 (6.8) 
20 (27.0) 
 
 
83 (24.3) 
37 (10.9) 
84 (24.6) 
18 (5.3) 
50 (14.7) 
 
 
1.00 
1.99 (0.64-6.17) 
5.70 (2.57-12.67) 
3.15 (1.03-9.62) 
6.12 (2.67-14.01) 
 
 
Yes 
 
 
1.00 
2.29 (0.76-6.97) 
6.26 (2.81-13.93) 
3.37 (1.10-10.34) 
6.44 (2.83-14.69) 
 
 
< 0.0001 
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Unknown 302 (20.1) 11 (14.9) 69 (20.2) 2.20 (0.88-5.47) 2.28 (0.93-5.63) 
Pathological response 
ypT0/is ypN0 
ypT+ ypN0 
ypT+ ypN+ 1-3 nodes 
ypT+ ypN+ ≥4 nodes 
 
278 (18.5) 
420 (27.9) 
450 (29.9) 
357 (23.7) 
 
16 (21.6) 
10 (13.5) 
14 (18.9)  
34 (45.9) 
 
24 (7.0) 
42 (12.3) 
121 (35.5) 
154 (45.2) 
 
1.00 
0.60 (0.26-1.37) 
0.68 (0.33-1.39) 
2.16 (1.11-4.02) 
 
Yes 
 
1.00 
0.58 (0.26-1.28) 
0.74 (0.36-1.52) 
2.43 (1.34-4.40) 
 
< 0.0001 
Surgical margins 
R0  
R1 
 
1398 (92.9) 
107 (7.1) 
 
65 (87.8) 
9 (12.2) 
 
309 (90.6) 
32 (9.4) 
 
1.00 
1.68 (0.75-3.75) 
 
No 
  
 
Abbreviations: HR: Hazard ratio, LRR: Locoregional recurrence, HER2: Human Epidermal  
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Supplementary file: EORTC 10994/BIG 1-00, Protocol Guidelines for Radiotherapy 
 
5.2.2.  GUIDELINES FOR RADIOTHERAPY 
5.2.2.1  Radiotherapy equipment should in all cases furnish megavoltage beams, 
namely telecobalt, high energy x-rays, and electron beams. Interstitial brachytherapy may be 
used for localised small-volume « boost » treatment. The use of modern treatment planning 
techniques, including simulation (either conventional simulator or CT-based simulation) and 
computer-assisted dosimetric calculations, is required.  
5.2.2.2  Choice of target volumes depend upon the clinical presentation and the extent 
of surgery, if any: 
- In the event of breast preservation (either with or without surgery), the entire breast and 
underlying chest wall must be irradiated.  
- After mastectomy, chest wall irradiation will be given to all patients with locally advanced 
cancers; for « large operable » lesions, the indication for chest wall irradiation will be 
assessed on a case-by-case basis by the treating radiation oncologist.  
- After axillary clearance (at least level I-II), axillary irradiation may be omitted if adequate 
control is expected without radiotherapy. Its use is optional at the discretion of the treating 
radiation oncologist. In the event of more limited axillary surgery, axillary irradiation is 
generally recommended, especially if nodal positivity is demonstrated. If axillary surgery is 
not performed, the axilla must be irradiated.  
- Supra- and infraclavicular irradiation is generally recommended for the patient 
population in this study. Irradiation of the ipsilateral internal mammary nodes (IMN) is 
optional, but should not unduly compromise the homogeneity of radiotherapy given to the 
breast and chest wall, and must be planned in such a way as to minimize radiation exposure 
to lung and heart. Internal mammary irradiation may be reasonable in patients with locally 
advanced disease, or those having clinical or histological axillary nodal involvement, 
particularly in the event of central or medial tumor location. 
5.2.2.3  Beam arrangements and dose specification  
- The breast and underlying chest wall are treated with two tangential photon beams, 
whose deep edges may be opposed to minimize lung irradiation. Both fields are to be 
treated daily. A half-beam technique is permissible. Breast dose should be prescribed at 
the intersection of the beam axes (ICRU 29). If this point is judged to be too close to the 
skin, or if a half-beam technique is used, the dose may be prescribed at a point in the center 
of the breast. Homogeneity guidelines recommend that dose within the target volume be 
within +10% and -5% of the prescribed dose. Wedge filters may be needed to achieve this 
goal. A computer-generated dose distribution is required in the central plane, and dose 
distribution calculations in two off-axis planes are recommended (but not required). 
Appropriate bolus should be used in cases with skin involvement. 
- For chest wall irradiation after mastectomy tangential beams can be used, as described 
above, or electron beams of appropriate energy may be employed. The target volume 
should encompass the surgical scar and the skin flaps delimiting the implantation site of the 
amputated breast, with adequate margins. Bolus should be used as clinically indicated. If 
electron beams are used, dose prescriptions should follow recommendations of ICRU 54. 
Electron energy should be chosen so that the 85% isodose corresponds to the mid-point of 
the ribs.  
- Axillary irradiation is generally accomplished with the same anterior photon beam used for 
supra/infraclavicular irradiation, but will usually require an additional posterior beam to 
bring the dose at axillary mid-plane to the level of the prescribed dose. The supraclavicular 
dose is prescribed at a depth of 3 cm. Angling of the supraclavicular field to minimize 
esophageal and spinal cord irradiation is allowed. 
- Internal mammary irradiation aims to treat the IMN in the first 4 ipsilateral interspaces, 
which are assumed to be situated at 3 cm from the midline, and at 3 cm depth. Use of an 
5-cm-wide anterior field of appropriate length (bordering medially on the midline) is 
acceptable, but the IMN may also be included in the tangential beams used to irradiate the 
breast/chest wall. Other techniques are also acceptable if they conform to the guidelines of 
EORTC Protocol 22922/10925. Actual depth and location of the nodes may vary 
considerably, especially if the breast is in place. Use of imaging techniques for treatment 
planning is recommended. If a direct IM field is used, an appropriate mixture of photon and 
electron beams should be used to minimize cardiac irradiation.  
- Boost irradiation includes the breast tumor bed in patients having had conservation 
surgery, and all sites of gross initial disease (prior to chemotherapy) that had not been 
excised. Boost irradiation can be given with localised megavoltage beams (preferably 
electrons, if feasible) or with interstitial brachytherapy. Boost volumes should include 
suspected residual disease with 2 cm circumferential margins (for the breast boost deep 
and superficial margins will be narrower). 
5.2.2.4  Prescribed doses  
- The recommended dose to the prescription point in all treatment volumes (breast/chest 
wall, axilla, infra/supraclavicular, IMN) is 50 Gy, given in 25 daily fractions of 2 Gy, five times 
weekly. Alternative dose prescriptions include 50.4 Gy (28 x 1.8 Gy, 5 times weekly), or 45 
Gy (18 x 2.5 Gy, 4 times weekly).  Other fractionation schedules can be considered by a 
study investigator. After conservation surgery, breast boost dose should be 16 Gy (8 x 2 
Gy) for external beam and 16 Gy (Paris system) for low-dose interstitial boost. An equivalent 
dose for high-dose-rate brachytherapy will be established.   
- Areas of unexcised initial gross disease in the breast/chest wall should receive boosts 
of 20-26 Gy. Boosts to unexcised initial gross disease in nodal areas should be limited (e.g. to 
10-16 Gy) according to considerations of normal tissue tolerance (plexus). 
 
Supplementary table 1: Simplified breast cancer subtype classification  
 
Abbreviations:  
ER: oestrogen receptor; PR: progesterone receptor; HER2: Human Epidermal growth factor 
Receptor 2; Trastu-: without adjuvant trastuzumab; Trastu+: with adjuvant trastuzumab; LRR: 
Locoregional recurrence; R0: negative surgical margins; R1: positive surgical margins. 
 
Legend:  
* Positive, negative or unknown.
Breast cancer  
subtype 
 
ER status PgR status Her2 status Tumor grade 
Luminal-A like 
 
 
ER+                  
and/or 
PgR+ Her2- Grade 1 or 2 
 
Luminal-B like 
HER2- 
 
ER+                  
and/or 
PgR+ Her2- Grade 3 
HER2+ 
 
 
Any* ER            
and/or 
PgR  
 
Her2+  
(IHC3+ or 
amplified) 
Any or 
unknown 
Triple 
Negative 
ER-                     PgR- Her2- Any or 
unknown 
Supplementary table 2: patients whose tumour achieved a pCR (ypT0/is ypN0) and 
presented with a locoregional relapse as first event 
 
 
 
 
Total 
(N=16) 
One site 
only 
(N=14) 
More than 
one site 
 
(N=2) 
 N (%) N (%) N (%) 
Local                                                                                                                                                                                                                               
 no                                                4 (28.6)                                                                                          0 (0.0)                                                                                           4 (25.0)                     
 yes                                              10 (71.4)                                                                                          2 (100.0)                    12 (75.0)                                                                                          
 
Chest wall                                      
                                                                                                                                                                                                                              
 no                                               14 
(100.0)                                                                                         
   2 (100.0)                                                                                         16 (100.0)                                                                                         
Axillary nodes                                                                                                                                                                                                                                                                
 no                                               13 (92.9)                                                                                          0 (0.0)                    13 (81.3)                                                                                          
 yes                                               1 (7.1)                                                                                           2 (100.0)                                                                         3 (18.8)                                     
 
Internal mammary nodes                          
                                                                                                                                                                                                                              
 no                                               14 
(100.0)                                                                                         
   2 (100.0)                                                                                         16 (100.0)                                                                                         
Infraclavicular nodes                                                                                                                                                                                                                                                         
 no                                               12 (85.7)                                                                                          2 (100.0)                    14 (87.5)                                                                                          
 yes                                               2 (14.3)                                                                                          0 (0.0)                                                                                           2 (12.5)                     
 
Supraclavicular nodes                           
                                                                                                                                                                                                                              
 no                                               13 (92.9)                                                                                          2 (100.0)                    15 (93.8)                                                                                          
 yes                                               1 (7.1)                                                                                           0 (0.0)                                                                                           1 (6.3)                     
 
 
Supplementary table 3: Validity of the primary results: multivariate Fine and Gray model, Cox 
model and bootstrap process based on Cox model analysis 
 
 
 Multivariate Fine and 
Gray model* 
Multivariate Cox 
model** 
 
Cox model 
Bootstrap 
 Backward 
procedure 
selection 
(Yes/No) 
Final 2-
sided p-
value 
(Gray test) 
Backward 
procedure 
selection 
(Yes/No) 
Final 2-
sided p-
value 
(Gray test) 
 
(% of 
inclusion) 
(N = 5000) 
Age at diagnosis No  No  44.2 
Clinical tumour 
status 
No  No  58.3  
Nodal tumour status No  No  20.7 
Histological type No  No  8.8 
Type of surgery No  No  24.8 
Breast cancer 
subtype/trastuzumab 
Yes < 0,0001 Yes < 0,0001 99.9 
Pathological 
response 
Yes < 0,0001 Yes < 0,0001 98.5 
Surgical margins No  No  39.8 
 
 
Legend: 
* with distant relapse as first relapse/death as event of interest and locoregional relapse as 
first relapse as competing risk 
** with locoregional as first relapse as first relapse as event of interest and where distant 
relapse as first relapse/deaths are censored 
